Novel therapies in urothelial carcinoma: a biomarker-driven approach

Annals of Oncology : Official Journal of the European Society for Medical Oncology
G Iyer, Jonathan E Rosenberg

Abstract

Urothelial malignancies, including carcinomas of the bladder, ureters, and renal pelvis comprised ∼8% of new cancer cases in the USA in 2016. In the metastatic setting, 15% of patients exhibit long-term survival following cisplatin-based chemotherapy and in patients with recurrent disease, response rates to second-line chemotherapy are generally 15%-20% with a 3-month progression-free survival. However, recent advances in immunotherapy represent an opportunity to significantly improve patient outcomes. Moreover, the advent of next-generation sequencing has resulted in both an improved understanding of the fundamental genetic changes that characterize urothelial carcinoma (UC) and identification of several candidate biomarkers of response to various therapies. Incorporation of prospective genotyping into clinical trials will allow for the identification and enrichment of patients most likely to respond to specific targeted therapies and chemotherapy. Combining different therapeutic classes to enhance outcomes is also an area of active research in UC.

References

Jan 6, 2001·Sexually Transmitted Infections·T PowlesM Bower
Aug 29, 2003·The New England Journal of Medicine·H Barton GrossmanE David Crawford
Jul 22, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hans von der MaaseMichael Arning
Aug 2, 2007·Proceedings of the National Academy of Sciences of the United States of America·Jae K LeeDan Theodorescu
Jul 29, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew I MilowskyDean F Bajorin
Jan 22, 2011·Neoplasia : an International Journal for Oncology Research·Steven C SmithDan Theodorescu
Jan 1, 2010·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·S KalraS Kumar
May 10, 2011·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·Lara P StepanClaire L Sutherland
Aug 28, 2012·Science·Gopa IyerDavid B Solit
Nov 24, 2012·Human Molecular Genetics·Sarah V WilliamsMargaret A Knowles
Apr 5, 2013·BJU International·Matthew I MilowskyDean F Bajorin
Jul 25, 2013·BJU International·Angela B Smith, Raj S Pruthi
Jan 31, 2014·Nature·UNKNOWN Cancer Genome Atlas Research Network
Aug 7, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J BellmuntUNKNOWN ESMO Guidelines Working Group
Jun 2, 2015·The New England Journal of Medicine·James LarkinJedd D Wolchok
Jun 17, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mehdi TouatJean-Charles Soria
Sep 2, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Josep TaberneroJean-Charles Soria
Oct 22, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D RaggiA Necchi
Feb 20, 2016·Aesthetic Plastic Surgery·Dennis Hurwitz
Apr 6, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Noura J ChoudhuryPeter H O'Donnell
Jul 14, 2016·Oncotarget·Ricardo CostaFrancis J Giles
Feb 1, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Min Yuen TeoJonathan E Rosenberg

❮ Previous
Next ❯

Citations

Jan 17, 2021·International Journal of Molecular Sciences·Javier Torres-JiménezJavier Molina-Cerrillo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Sequencing

Several sequencing approaches are employed to understand and examine tumor development and progression. These include whole genome as well as RNA sequencing. Here is the latest research on cancer sequencing.

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.

© 2022 Meta ULC. All rights reserved